Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSinolife Utd
Stock Code03332
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家快速成長的營養膳食補充劑零售商,製造並透過中國一二線城市的自營零售店銷售兩個主要品牌中生及康培爾旗下的優質及安全的營養膳食補充劑。於2013年6月30日,在中國一線及二線城市合共經營49家自營零售店。
Listing Date2014-01-15
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省南京玄武區長江路188號德基大廈30樓
Business Address (Hong Kong)香港康樂廣場1號怡和大廈40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitezs-united.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 2.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.1 / shares
Offer Period2014-01-08 to 2014-01-08
Global Offering Shares203,800,000 shares
HK Public Offer Shares (Initial)20,380,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)183,420,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO814,911,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share2.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 407,600,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 177.6M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +5369%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣57.2百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-06
Revenue 66,850103,244150,37285,965
Cost of sales -13,588-20,080-20,276-11,264
Gross profit 53,26283,164130,09674,701
Other income and gains, net 6793371,484581
Selling and distribution expenses -18,732-20,339-34,047-22,216
Administrative expenses -14,214-15,955-20,621-12,788
Profit before tax 20,99547,20776,91240,278
Income tax expense -5,207-12,393-19,675-10,578
Profit for the year 15,78834,81457,23729,700
Profit attributable to owners 15,78834,81457,23729,700
Balance Sheet
Item 2010201120122013-06
Cash and cash equivalents 36,30662,77593,220128,383
Trade and bills receivables 3,4465,9893,7314,188
Inventories 5,43810,94413,6849,962
Total current assets 45,97089,558111,427164,634
Total assets 71,007113,896139,631193,128
Total current liabilities 10,52018,70320,11820,327
Total liabilities 10,52018,70320,11820,327
Total equity 60,48795,193119,513172,801
Equity attributable to owners 60,48795,193119,513172,801
Cash Flow Statement
Item 2010201120122013-06
Net cash from operating activities 17,34735,18157,92335,396
Net cash from investing activities -124-8,8354,670-23,937
Net cash from financing activities -12,836340-32,30724,486
Net increase in cash 4,38726,68630,28635,945
Depreciation of PP&E 2,2032,0911,9821,389
Amortisation of intangible assets 65656533
Purchase of PP&E -550-246-2,390-2,364
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.66
First Day OpenHK$ 2.78
First Day Change33.00%
First Day Volume179746000.0
First Day Turnover492908000.0
Use of Proceeds
1、約43%(或143.6百萬港元)將用于擴張我們位于江蘇省南京市的生產設施,其中: a 約31%(或103.6百萬港元)將用于建設一條新生產線,以制造軟膠囊劑、罐裝粉劑及迷你瓶裝飲料形式的產品,設計年產能分別為800,000劑、650,000劑及2,000,000劑; b 約6%(或20.0百萬港元)將用于建設一個研發測試中心;及 c 約6%(或20.0百萬港元)將用于設立一個信息及物流控制中心; 2、約34%(或113.5百萬港元)將于未來兩年內用于為我們的營銷及推廣活動提供資金,借以提高中生及康培爾品牌在全國范圍內的品牌知名度,其中: a 約23%(或76.8百萬港元)將用于電視、印刷品、電臺及網上廣告; b 約6%(或20.0百萬港元)將用于聘請明星代言人; c 約3%(或10.0百萬港元)將用于通過創作及推出新企業宣傳片、新產品包裝設計及新營銷材料以推廣及提升我們的企業及品牌形象; d 約2%(或6.7百萬港元)將用于在主要節假日于中國各地舉行的推廣活動; 3、 約18%(或68.5百萬港元)將用于在未來數年內加強及擴張我們的現有銷售網絡,并滲透至新區域,尤其是中國一線城市、省會及富裕的二線城市,其中: a 約6%(或22.8百萬港元)將用于支持我們2014年的銷售網絡擴張。根據當前的市況,我們現擬在2014年年底前分別將中生零售店數目及康培爾零售店數目增加至45家及72家; b 約12%(或45.7百萬港元)將用于支持我們2015年及2016年的銷售網絡擴張。視乎當時的宏觀經濟環境及我們產品的市場需求,按開設中生零售店及康培爾零售店的最低資金需求計算,所得款項將足以讓我們在2015年及2016年分別再開設20家及80家中生零售店及康培爾零售店; 4、余下約5%(或19百萬港元)將用作我們的營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Overall Coordinators (1)
交银国际证券有限公司 CE APJ121
Joint Bookrunners (1)
交银国际证券有限公司 CE APJ121
Joint Lead Managers (1)
交银国际证券有限公司 CE APJ121

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 康健企业咨询及投资有限公司 44,304,000 HKD — 2.70% — 6 months 2014-07-15

Directors & Management

PositionChinese nameEnglish Name
Chairman桂平湖—
Company Secretary支卉、甘美霞—
No director data available.

Major Shareholders

Major Shareholders & Holdings桂先生持有內資股476,685,000股,佔全球發售後本公司股本總額約58.50%;其配偶吳女士持有52,965,000股,佔約6.50%;上海復星持有61,111,000股,佔約7.50%。
About this page

This page shows Sinolife Utd (03332) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect